JP2017509643A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017509643A5 JP2017509643A5 JP2016557946A JP2016557946A JP2017509643A5 JP 2017509643 A5 JP2017509643 A5 JP 2017509643A5 JP 2016557946 A JP2016557946 A JP 2016557946A JP 2016557946 A JP2016557946 A JP 2016557946A JP 2017509643 A5 JP2017509643 A5 JP 2017509643A5
- Authority
- JP
- Japan
- Prior art keywords
- human
- seq
- amino acid
- acid sequence
- binds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461955663P | 2014-03-19 | 2014-03-19 | |
| US61/955,663 | 2014-03-19 | ||
| US201461981641P | 2014-04-18 | 2014-04-18 | |
| US61/981,641 | 2014-04-18 | ||
| US201462007385P | 2014-06-03 | 2014-06-03 | |
| US62/007,385 | 2014-06-03 | ||
| US201462033460P | 2014-08-05 | 2014-08-05 | |
| US62/033,460 | 2014-08-05 | ||
| PCT/US2015/021322 WO2015143079A1 (en) | 2014-03-19 | 2015-03-18 | Antibody compositions for tumor treatment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019130949A Division JP6831426B2 (ja) | 2014-03-19 | 2019-07-16 | 腫瘍治療のための抗体組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017509643A JP2017509643A (ja) | 2017-04-06 |
| JP2017509643A5 true JP2017509643A5 (enExample) | 2018-04-26 |
| JP6559697B2 JP6559697B2 (ja) | 2019-08-14 |
Family
ID=52808172
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016557946A Active JP6559697B2 (ja) | 2014-03-19 | 2015-03-18 | 腫瘍治療のための抗体組成物 |
| JP2019130949A Active JP6831426B2 (ja) | 2014-03-19 | 2019-07-16 | 腫瘍治療のための抗体組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019130949A Active JP6831426B2 (ja) | 2014-03-19 | 2019-07-16 | 腫瘍治療のための抗体組成物 |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US10550193B2 (enExample) |
| EP (3) | EP3119808B1 (enExample) |
| JP (2) | JP6559697B2 (enExample) |
| KR (1) | KR102435081B1 (enExample) |
| CN (2) | CN106459214B (enExample) |
| AU (1) | AU2015231295C1 (enExample) |
| CA (1) | CA2943084C (enExample) |
| CY (2) | CY1122315T1 (enExample) |
| DK (2) | DK3594238T3 (enExample) |
| EA (1) | EA035164B1 (enExample) |
| ES (2) | ES2752156T3 (enExample) |
| FI (1) | FIC20240044I1 (enExample) |
| FR (1) | FR25C1001I2 (enExample) |
| HR (1) | HRP20192170T1 (enExample) |
| HU (3) | HUE054397T2 (enExample) |
| IL (2) | IL247845B (enExample) |
| LT (3) | LT3594238T (enExample) |
| MA (1) | MA55629A (enExample) |
| ME (1) | ME03544B (enExample) |
| MX (2) | MX373927B (enExample) |
| NL (1) | NL301302I2 (enExample) |
| NO (1) | NO2024056I1 (enExample) |
| PL (2) | PL3594238T3 (enExample) |
| PT (2) | PT3594238T (enExample) |
| RS (2) | RS59642B1 (enExample) |
| SI (2) | SI3594238T1 (enExample) |
| SM (2) | SMT201900662T1 (enExample) |
| TW (2) | TWI701042B (enExample) |
| WO (1) | WO2015143079A1 (enExample) |
| ZA (1) | ZA201606597B (enExample) |
Families Citing this family (191)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| US12466897B2 (en) | 2011-10-10 | 2025-11-11 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
| US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
| US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
| US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
| US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
| CN105051069B (zh) | 2013-01-14 | 2019-12-10 | Xencor股份有限公司 | 新型异二聚体蛋白 |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
| US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
| AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| EP3421495A3 (en) | 2013-03-15 | 2019-05-15 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
| KR102225489B1 (ko) | 2013-12-17 | 2021-03-10 | 제넨테크, 인크. | 항-cd3 항체 및 이의 사용 방법 |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| TWI701042B (zh) * | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| KR102497443B1 (ko) | 2014-03-28 | 2023-02-08 | 젠코어 인코포레이티드 | Cd38 및 cd3에 결합하는 이중특이적 항체 |
| SG11201701627PA (en) | 2014-09-12 | 2017-03-30 | Genentech Inc | Anti-cll-1 antibodies and immunoconjugates |
| AU2015350075B2 (en) * | 2014-11-17 | 2021-06-03 | Regeneron Pharmaceuticals, Inc. | Methods for tumor treatment using CD3xCD20 bispecific antibody |
| KR20240055876A (ko) | 2014-11-24 | 2024-04-29 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화 cd3 복합체를 발현하는 비인간 동물 |
| CA2967426A1 (en) | 2014-11-26 | 2016-06-02 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and tumor antigens |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| BR112017011166A2 (pt) | 2014-11-26 | 2018-02-27 | Xencor, Inc. | anticorpos heterodiméricos que se ligam a cd3 e cd38 |
| EP3237449A2 (en) | 2014-12-22 | 2017-11-01 | Xencor, Inc. | Trispecific antibodies |
| UA120286C2 (uk) | 2015-01-08 | 2019-11-11 | Ґенмаб А/С | Біспецифічне антитіло проти cd3 і cd20 |
| WO2016141387A1 (en) | 2015-03-05 | 2016-09-09 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
| US10556952B2 (en) | 2015-03-30 | 2020-02-11 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to Fc gamma receptors |
| EA039429B1 (ru) * | 2015-05-13 | 2022-01-26 | Ридженерон Фармасьютикалз, Инк. | Способы лечения опухолей с применением биспецифического антитела cd3xcd20 |
| ES2957567T3 (es) | 2015-06-16 | 2024-01-22 | Hoffmann La Roche | Anticuerpos humanizados y de afinidad madurada contra FcRH5 y procedimientos de uso |
| EP3916018A1 (en) | 2015-06-16 | 2021-12-01 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
| TW201718647A (zh) | 2015-06-16 | 2017-06-01 | 建南德克公司 | 抗-cll-1抗體及使用方法 |
| JP6837436B2 (ja) * | 2015-07-10 | 2021-03-03 | 中外製薬株式会社 | 内因性ｃｄ３遺伝子をヒトｃｄ３遺伝子に置換した非ヒト動物 |
| JOP20160154B1 (ar) | 2015-07-31 | 2021-08-17 | Regeneron Pharma | أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها |
| TWI899515B (zh) | 2015-08-04 | 2025-10-01 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
| TWI784917B (zh) | 2015-09-23 | 2022-11-21 | 美商再生元醫藥公司 | 最優化抗ｃｄ３雙特異性抗體及其用途 |
| CN108699136B (zh) | 2015-12-07 | 2022-03-18 | Xencor股份有限公司 | 结合cd3和psma的异二聚抗体 |
| EA201891495A1 (ru) * | 2015-12-22 | 2018-11-30 | Ридженерон Фармасьютикалз, Инк. | Биспецифические анти-cd20/анти-cd3 антитела для лечения острого лимфобластного лейкоза |
| MA44146B1 (fr) * | 2015-12-22 | 2023-10-31 | Regeneron Pharma | Combinaison d'anticorps anti-pd-1 et d'anticorps bispécifiques anti-cd20/anti-cd3 pour traiter le cancer |
| US11236174B2 (en) | 2016-01-12 | 2022-02-01 | Crescendo Biologics Limited | Therapeutic molecules |
| SG11201807881VA (en) | 2016-04-20 | 2018-10-30 | Regeneron Pharma | Compositions and methods for making antibodies based on use of an expression-enhancing locus |
| KR102906454B1 (ko) | 2016-04-20 | 2026-01-02 | 리제너론 파마슈티칼스 인코포레이티드 | 발현 강화 유전자좌의 사용에 기초하여 항체를 만들기 위한 조성물 및 방법 |
| GB201607968D0 (en) | 2016-05-06 | 2016-06-22 | Crescendo Biolog Ltd | Chimeric antigen receptor |
| TWI786044B (zh) | 2016-05-13 | 2022-12-11 | 美商再生元醫藥公司 | 藉由投予ｐｄ-１抑制劑治療皮膚癌之方法 |
| EP3464370A1 (en) * | 2016-06-01 | 2019-04-10 | Xencor, Inc. | Bispecific antibodies that bind cd20 and cd3 for use in the treatment of lymphoma |
| CA3026151A1 (en) | 2016-06-14 | 2017-12-21 | Xencor, Inc. | Bispecific checkpoint inhibitor antibodies |
| WO2017223111A1 (en) * | 2016-06-21 | 2017-12-28 | Teneobio, Inc. | Cd3 binding antibodies |
| MX2018016265A (es) | 2016-06-28 | 2019-07-04 | Xencor Inc | Anticuerpos heterodimericos que se unen al receptor 2 de somatostatina. |
| EP3502250B1 (en) | 2016-08-22 | 2024-04-24 | Chugai Seiyaku Kabushiki Kaisha | Gene-modified rodent expressing human gpc3 polypeptide |
| WO2018039499A1 (en) | 2016-08-24 | 2018-03-01 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
| US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| HRP20240767T1 (hr) * | 2016-09-14 | 2024-09-13 | Teneoone, Inc. | Cd3 vezujuća antitijela |
| HRP20221202T1 (hr) * | 2016-09-23 | 2022-12-09 | Regeneron Pharmaceuticals, Inc. | Anti-muc16 (mucin 16) antitijela |
| PE20240950A1 (es) | 2016-10-14 | 2024-05-06 | Xencor Inc | PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa) |
| US11466094B2 (en) * | 2016-11-15 | 2022-10-11 | Genentech, Inc. | Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies |
| BR112019012354A2 (pt) | 2016-12-21 | 2019-11-26 | Teneobio, Inc. | anticorpos apenas de cadeia pesada anti-bcma |
| EP3565842A1 (en) | 2017-01-06 | 2019-11-13 | Crescendo Biologics Limited | Single domain antibodies to programmed cell death (pd-1) |
| IL321717A (en) | 2017-02-21 | 2025-08-01 | Regeneron Pharma | Anti-PD-1 antibodies for the treatment of lung cancer |
| US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| JOP20190222A1 (ar) * | 2017-04-11 | 2019-09-24 | Zymeworks Inc | الأجسام المضادة ثنائية النوعية المضادة لـ pd-l1 والمضادة لـ tim-3 |
| CN110891971B (zh) | 2017-06-20 | 2024-01-12 | 特尼奥生物股份有限公司 | 仅有重链的抗bcma抗体 |
| MX2019015563A (es) | 2017-06-20 | 2020-07-28 | Teneoone Inc | Anticuerpos anti-bcma unicamente de cadena pesada. |
| US10882907B2 (en) | 2017-06-21 | 2021-01-05 | Gilead Sciences, Inc. | Multispecific antibodies that target HIV GP120 and CD3 |
| AU2018291497A1 (en) | 2017-06-30 | 2020-01-16 | Xencor, Inc. | Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains |
| CN114075269A (zh) | 2017-07-06 | 2022-02-22 | 菲仕兰坎皮纳荷兰私人有限公司 | 用于制备糖蛋白的细胞培养工艺 |
| GB201711068D0 (en) | 2017-07-10 | 2017-08-23 | Crescendo Biologics Ltd | Therapeutic molecules binding PSMA |
| TWI799432B (zh) * | 2017-07-27 | 2023-04-21 | 美商再生元醫藥公司 | 抗ctla-4抗體及其用途 |
| KR20200044806A (ko) * | 2017-07-28 | 2020-04-29 | 내셔널 유니버시티 오브 싱가포르 | 변형된 유령 세포를 포함하는 생물분자 복합체 |
| EP3661555B1 (en) * | 2017-08-01 | 2025-04-16 | Ab Therapeutics, Inc. | Bispecific antibodies and uses thereof |
| KR20200085828A (ko) | 2017-11-08 | 2020-07-15 | 젠코어 인코포레이티드 | 신규의 항-pd-1 서열을 사용한 이중특이적 및 단일특이적 항체 |
| US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| JP7312168B2 (ja) | 2017-11-13 | 2023-07-20 | クレッシェンド、バイオロジックス、リミテッド | Ｃｄ１３７に結合するシングルドメイン抗体 |
| EP3728302A1 (en) | 2017-12-19 | 2020-10-28 | Xencor, Inc. | Engineered il-2 fc fusion proteins |
| CN111479618B (zh) | 2017-12-22 | 2022-08-02 | 瑞泽恩制药公司 | 用于表征药物产品杂质的系统和方法 |
| CA3086665A1 (en) | 2017-12-22 | 2019-06-27 | Teneobio, Inc. | Heavy chain antibodies binding to cd22 |
| KR20200115485A (ko) | 2018-01-31 | 2020-10-07 | 리제너론 파마슈티칼스 인코포레이티드 | 약물 생성물 불순물을 특성화하기 위한 시스템 및 방법 |
| TWI786265B (zh) | 2018-02-02 | 2022-12-11 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
| CN118772287A (zh) | 2018-02-08 | 2024-10-15 | 豪夫迈·罗氏有限公司 | 双特异性抗原结合分子和使用方法 |
| GB201802573D0 (en) | 2018-02-16 | 2018-04-04 | Crescendo Biologics Ltd | Therapeutic molecules that bind to LAG3 |
| US12460270B2 (en) | 2018-02-28 | 2025-11-04 | Regeneron Pharmaceuticals, Inc. | Systems and methods for identifying viral contaminants |
| IL277049B2 (en) | 2018-03-13 | 2024-02-01 | Zymeworks Bc Inc | Conjugates of biparatopic anti-HER2 antibody and drug and methods of use |
| BR112020015291B1 (pt) | 2018-03-19 | 2023-09-26 | Regeneron Pharmaceuticals, Inc | Tampão de amostra de eletroforese aquoso, método para identificar contaminantes ou impurezas em uma amostra de fármaco proteico, e, kit |
| US12253490B2 (en) | 2018-03-19 | 2025-03-18 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| US12259355B2 (en) | 2018-03-19 | 2025-03-25 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| EP3773911A2 (en) | 2018-04-04 | 2021-02-17 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
| KR20210003814A (ko) | 2018-04-18 | 2021-01-12 | 젠코어 인코포레이티드 | IL-15/IL-15Rα Fc-융합 단백질 및 TIM-3 항원 결합 도메인을 함유하는 TIM-3 표적화 이종이량체 융합 단백질 |
| MX2020010910A (es) | 2018-04-18 | 2021-02-09 | Xencor Inc | Proteinas de fusion heterodimericas dirigidas a pd-1 que contienen proteinas de fusion il-15 / il-15ra fc y dominios de union al antigeno pd-1 y usos de los mismos. |
| TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
| EP3569617A1 (en) * | 2018-05-18 | 2019-11-20 | Trion Research GmbH | Pharmaceutical preparation for use in treating epstein- barr virus positive patients with reactivation phenomenon- associated diseases |
| CN110540593B (zh) * | 2018-05-29 | 2022-05-17 | 上海药明生物技术有限公司 | 新型的抗cd3/抗cd20双特异性抗体 |
| TWI890661B (zh) | 2018-06-21 | 2025-07-21 | 美商再生元醫藥公司 | 用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症的方法 |
| CN112218877B (zh) | 2018-08-27 | 2025-07-25 | 瑞泽恩制药公司 | 拉曼光谱在下游纯化中的应用 |
| KR20210053816A (ko) | 2018-08-30 | 2021-05-12 | 리제너론 파마슈티칼스 인코포레이티드 | 단백질 복합체를 특성화하기 위한 방법 |
| IL280875B2 (en) | 2018-08-31 | 2024-12-01 | Regeneron Pharma | Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies |
| MX2021003765A (es) | 2018-10-03 | 2021-07-15 | Xencor Inc | Proteínas il-12 de fusión a fc heterodimérico. |
| CN109836502B (zh) * | 2018-11-12 | 2021-09-07 | 浙江大学 | 一种双特异性抗体及其应用 |
| IL284471B2 (en) | 2019-01-16 | 2025-01-01 | Regeneron Pharma | Methods for identifying free thiols in proteins |
| CN111484555B (zh) * | 2019-01-28 | 2022-07-08 | 正大天晴药业集团股份有限公司 | 新型双特异性cd3/cd20多肽复合物 |
| US12463463B2 (en) | 2019-01-28 | 2025-11-04 | Ab Therapeutics, Inc. | Bispecific antibodies and uses thereof |
| WO2020156405A1 (en) * | 2019-01-28 | 2020-08-06 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel bispecific cd3/cd20 polypeptide complexes |
| US12459991B2 (en) | 2019-02-12 | 2025-11-04 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for using bispecific antibodies to bind complement and a target antigen |
| AU2020232605A1 (en) | 2019-03-01 | 2021-10-21 | Xencor, Inc. | Heterodimeric antibodies that bind ENPP3 and CD3 |
| AU2020252556B2 (en) | 2019-04-05 | 2026-02-05 | Teneobio, Inc. | Heavy chain antibodies binding to PSMA |
| EP3969908A1 (en) | 2019-05-13 | 2022-03-23 | Regeneron Pharmaceuticals, Inc. | Improved competitive ligand binding assays |
| CR20210622A (es) | 2019-06-14 | 2022-06-27 | Teneobio Inc | Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3 |
| EP3998081A4 (en) | 2019-07-05 | 2023-07-12 | Ono Pharmaceutical Co., Ltd. | TREATMENT OF BLOOD CANCER WITH PD-1/CD3 DUAL SPECIFICITY PROTEIN |
| EP4653865A3 (en) | 2019-09-24 | 2026-02-18 | Regeneron Pharmaceuticals, Inc. | Systems and methods for chromatography use and regeneration |
| US12297451B1 (en) | 2019-10-25 | 2025-05-13 | Regeneron Pharmaceuticals, Inc. | Cell culture medium |
| MX2022006236A (es) | 2019-11-25 | 2022-06-22 | Regeneron Pharma | Formulaciones de liberacion sostenida con emulsiones no acuosas. |
| PE20221511A1 (es) | 2019-12-13 | 2022-10-04 | Genentech Inc | Anticuerpos anti-ly6g6d y metodos de uso |
| KR102544013B1 (ko) | 2020-01-21 | 2023-06-19 | 리제너론 파마슈티칼스 인코포레이티드 | 당질화된 단백질의 전기영동을 위한 탈당질화 방법 |
| MX2022013453A (es) | 2020-04-29 | 2022-11-16 | Teneobio Inc | Anticuerpos de cadena pesada multiespecificos con regiones constantes de cadena pesada modificadas. |
| US20210341487A1 (en) | 2020-05-01 | 2021-11-04 | Regeneron Pharmaceuticals, Inc. | Neutralizing antibody assay for therapeutic proteins |
| CA3176436A1 (en) | 2020-05-08 | 2021-11-11 | Tahamtan Ahmadi | Bispecific antibodies against cd3 and cd20 |
| US11919956B2 (en) | 2020-05-14 | 2024-03-05 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 |
| WO2022022464A1 (zh) | 2020-07-27 | 2022-02-03 | 正大天晴药业集团股份有限公司 | 新型双特异性抗cd3/cd20多肽复合物配制剂 |
| JP7773528B2 (ja) | 2020-08-19 | 2025-11-19 | ゼンコア インコーポレイテッド | 抗ｃｄ２８組成物 |
| CA3192999A1 (en) | 2020-08-31 | 2022-03-03 | Regeneron Pharmaceuticals, Inc. | Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants |
| US20240034812A1 (en) | 2020-09-10 | 2024-02-01 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
| JP2023542289A (ja) | 2020-09-10 | 2023-10-06 | ジェンマブ エー／エス | 濾胞性リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体 |
| CN116406293A (zh) | 2020-09-10 | 2023-07-07 | 健玛保 | 用于治疗滤泡性淋巴瘤的联合疗法中的针对cd3和cd20的双特异性抗体 |
| JP2023541858A (ja) | 2020-09-10 | 2023-10-04 | ジェンマブ エー／エス | 慢性リンパ球性白血病を治療するためのｃｄ３及びｃｄ２０に対する二重特異性抗体 |
| JP2023542291A (ja) | 2020-09-10 | 2023-10-06 | ジェンマブ エー／エス | びまん性大細胞型ｂ細胞リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体 |
| EP4222171A1 (en) * | 2020-10-02 | 2023-08-09 | Regeneron Pharmaceuticals, Inc. | Combination of antibodies for treating cancer with reduced cytokine release syndrome |
| CA3196191A1 (en) | 2020-11-04 | 2022-05-12 | Chi-Chung Li | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates |
| CA3196539A1 (en) | 2020-11-04 | 2022-05-12 | Chi-Chung Li | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
| IL302400A (en) | 2020-11-04 | 2023-06-01 | Genentech Inc | Subcutaneous dosing of bispecific anti-CD20/anti-CD3 antibodies |
| EP4251128A1 (en) | 2020-11-25 | 2023-10-04 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous membrane emulsification |
| WO2022133135A1 (en) | 2020-12-17 | 2022-06-23 | Regeneron Pharmaceuticals, Inc. | Fabrication of protein-encapsulating microgels |
| CN116761880A (zh) | 2021-01-20 | 2023-09-15 | 瑞泽恩制药公司 | 改进细胞培养物中的蛋白质滴度的方法 |
| SI4284512T1 (sl) | 2021-01-28 | 2025-06-30 | Regeneron Pharmaceuticals, Inc. | Sestavki in postopki za zdravljenje sindroma sproščanja citokinov |
| CA3207883A1 (en) | 2021-03-03 | 2022-09-09 | Xiaobin Xu | Systems and methods for quantifying and modifying protein viscosity |
| CA3212665A1 (en) | 2021-03-09 | 2022-09-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
| KR20230154311A (ko) | 2021-03-10 | 2023-11-07 | 젠코어 인코포레이티드 | Cd3 및 gpc3에 결합하는 이종이량체 항체 |
| CA3210971A1 (en) | 2021-03-12 | 2022-09-15 | Bart-Jan DE KREUK | Non-activating antibody variants |
| US20220309215A1 (en) | 2021-03-26 | 2022-09-29 | Regeneron Pharmaceuticals, Inc. | Methods and systems for developing mixing protocols |
| AU2021443318A1 (en) | 2021-04-30 | 2023-09-07 | F. Hoffmann-La Roche Ag | Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate |
| WO2022241235A1 (en) | 2021-05-14 | 2022-11-17 | Genentech, Inc. | Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin |
| AU2022286340A1 (en) | 2021-06-01 | 2024-01-04 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| US12227574B2 (en) | 2021-06-17 | 2025-02-18 | Amberstone Biosciences, Inc. | Anti-CD3 constructs and uses thereof |
| WO2023039457A1 (en) | 2021-09-08 | 2023-03-16 | Regeneron Pharmaceuticals, Inc. | A high-throughput and mass-spectrometry-based method for quantitating antibodies and other fc-containing proteins |
| AU2022348521A1 (en) | 2021-09-20 | 2024-04-04 | Regeneron Pharmaceuticals, Inc. | Methods of controlling antibody heterogeneity |
| CN118076894A (zh) | 2021-10-07 | 2024-05-24 | 里珍纳龙药品有限公司 | pH建模和控制的系统及方法 |
| KR20240090312A (ko) | 2021-10-07 | 2024-06-21 | 리제너론 파아마슈티컬스, 인크. | Ph 미터 보정 및 교정 |
| KR20240097864A (ko) | 2021-10-26 | 2024-06-27 | 리제너론 파마슈티칼스 인코포레이티드 | 상이한 온도에서 실험실 용수를 생성하고 실험실 용수를 분배하는 시스템 및 방법 |
| IL312813A (en) | 2021-11-24 | 2024-07-01 | Regeneron Pharma | Methods for treating cancer using bispecific antibodies against CD3 and MUC16 and antibodies against CTLA-4 |
| KR20240130137A (ko) | 2022-01-07 | 2024-08-28 | 리제너론 파아마슈티컬스, 인크. | 이중특이적 항-MUC16 x 항-CD3 항체 단독으로 또는 항-PD-1 항체와의 조합으로 재발성 난소암을 치료하는 방법 |
| JP2025509567A (ja) | 2022-03-17 | 2025-04-11 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 再発性類上皮肉腫を、二重特異性抗ＭＵＣ１６ｘ 抗ＣＤ３抗体単独で、または抗ＰＤ－１抗体と組み合わせて治療する方法 |
| CA3245647A1 (en) | 2022-03-18 | 2023-09-21 | Regeneron Pharmaceuticals, Inc. | METHODS AND SYSTEMS FOR ANALYZING POLYPEPTIDE VARIANTS |
| US20230357446A1 (en) | 2022-04-11 | 2023-11-09 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
| WO2023201291A1 (en) | 2022-04-13 | 2023-10-19 | Genentech, Inc. | Pharmaceutical compositions of mosunetuzumab and methods of use |
| US20250164501A1 (en) | 2022-05-02 | 2025-05-22 | Regeneron Pharmaceuticals, Inc. | Biochemical assays for therapeutic proteins |
| AU2023269545A1 (en) | 2022-05-12 | 2024-11-14 | BioNTech SE | Binding agents capable of binding to cd27 in combination therapy |
| US20250304714A1 (en) | 2022-05-16 | 2025-10-02 | Regeneron Pharmaceuticals, Inc. | Methods of Treating Metastatic Castration-Resistant Prostate Cancer with Bispecific Anti-PSMA x Anti-CD3 Antibodies Alone or in Combination with Anti-PD-1 Antibodies |
| KR20250011926A (ko) | 2022-05-18 | 2025-01-22 | 리제너론 파마슈티칼스 인코포레이티드 | Cd38 및 4-1bb에 결합하는 다중특이적 항원 결합 분자, 및 이의 용도 |
| WO2024030453A1 (en) | 2022-08-02 | 2024-02-08 | Regeneron Pharmaceuticals, Inc. | Methods of treating metastatic castration-resistant prostate cancer with bispecific anti-psma x anti-cd28 antibodies in combination with anti-pd-1 antibodies |
| CA3265104A1 (en) * | 2022-08-19 | 2024-02-22 | Eli Lilly And Company | PD-1 AGONIST ANTIBODIES AND METHODS OF TREATMENT OF AUTOIMMUNE DISEASES WITH A PD-1 AGONIST ANTIBODY |
| TW202435942A (zh) | 2022-12-16 | 2024-09-16 | 美商里珍納龍藥品有限公司 | 評估層析管柱完整性的方法及系統 |
| US20240245779A1 (en) | 2023-01-25 | 2024-07-25 | Regeneron Pharmaceuticals, Inc. | Methods of modeling liquid protein composition stability |
| TW202445126A (zh) | 2023-01-25 | 2024-11-16 | 美商再生元醫藥公司 | 基於質譜法之體內共表現抗體之表徵 |
| TW202445138A (zh) | 2023-02-01 | 2024-11-16 | 美商再生元醫藥公司 | 用於生物巨分子分析之具質譜法的不對稱流場流分離 |
| IL322545A (en) | 2023-02-17 | 2025-10-01 | Regeneron Pharma | Induced NK cells responding to bispecific CD3/TAA antibodies |
| WO2024178213A2 (en) | 2023-02-22 | 2024-08-29 | Regeneron Pharmaceuticals, Inc. | System suitability parameters and column aging |
| EP4676972A1 (en) * | 2023-03-10 | 2026-01-14 | Joint Stock Company "Biocad" | Isolated bispecific antibody that specifically binds to cd3 and tumor antigen, and use thereof |
| TW202508625A (zh) | 2023-05-01 | 2025-03-01 | 美商再生元醫藥公司 | 使用苯酚或苯甲醇之多劑量抗體藥物產品 |
| CN121604974A (zh) | 2023-08-02 | 2026-03-03 | 瑞泽恩制药公司 | 用双特异性抗psma x抗CD28抗体治疗转移性去势抵抗性前列腺癌的方法 |
| WO2025030044A1 (en) | 2023-08-02 | 2025-02-06 | Regeneron Pharmaceuticals, Inc. | Methods of treating clear cell renal cell carcinoma with bispecific anti-psma x anti-cd28 antibodies |
| US20250086164A1 (en) | 2023-09-08 | 2025-03-13 | Regeneron Pharmaceuticals, Inc. | Methods and systems for assessing chromatographic column integrity |
| WO2025064403A2 (en) | 2023-09-18 | 2025-03-27 | Regeneron Pharmaceuticals, Inc. | Methods and systems for developing chromatography protocols |
| US20250109905A1 (en) | 2023-09-29 | 2025-04-03 | Regeneron Pharmaceuticals, Inc. | Lyophilization using controlled nucleation |
| US20250129117A1 (en) | 2023-10-18 | 2025-04-24 | Regeneron Pharmaceuticals, Inc. | Rapid purification of monoclonal antibody from in-process upstream cell culture material |
| US20250145662A1 (en) | 2023-11-02 | 2025-05-08 | Regeneron Pharmaceuticals, Inc. | Methods for reducing lipase activity using stress |
| TW202539732A (zh) | 2023-11-29 | 2025-10-16 | 美商再生元醫藥公司 | 以雙特異性抗muc16×抗cd28抗體與抗pd-1抗體之組合或與雙特異性抗muc16×抗cd3抗體之組合治療復發性卵巢癌及子宮內膜癌之方法 |
| TW202542187A (zh) | 2023-12-12 | 2025-11-01 | 美商再生元醫藥公司 | 以雙特異性抗muc16x抗cd3抗體單獨或與抗pd-1抗體組合治療子宮內膜癌之方法 |
| US20250242018A1 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration |
| TW202540428A (zh) | 2024-01-26 | 2025-10-16 | 美商雷傑納榮製藥公司 | 使用漿細胞耗乏劑及／或ｂ細胞耗乏劑遏制宿主抗ａａｖ抗體反應且實現ａａｖ轉導及重複給藥的方法及組成物 |
| WO2025166281A1 (en) | 2024-02-01 | 2025-08-07 | Regeneron Pharmaceuticals, Inc. | Platform for charge-detection mass spectrometry analysis of aavs |
| WO2025171124A1 (en) | 2024-02-07 | 2025-08-14 | Regeneron Pharmaceuticals, Inc. | Methods of treating prostate cancer with bispecific anti-psma x anti-cd3 antibodies and bispecific anti-psma x anti-cd28 antibodies |
| WO2025175164A1 (en) | 2024-02-16 | 2025-08-21 | Regeneron Pharmaceuticals, Inc. | Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods |
| US20250276092A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
| WO2025194043A1 (en) | 2024-03-15 | 2025-09-18 | Regeneron Pharmaceuticals, Inc. | Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations |
| WO2025240287A1 (en) | 2024-05-13 | 2025-11-20 | Regeneron Pharmaceuticals, Inc. | Methods of treating light chain amyloidosis with bispecific bcma x cd3 antibodies |
| WO2025244973A1 (en) | 2024-05-20 | 2025-11-27 | Regeneron Pharmaceuticals, Inc. | Methods of treating multiple myeloma with bispecific bcma x cd3 antibodies |
| WO2025259840A1 (en) | 2024-06-13 | 2025-12-18 | Regeneron Pharmaceuticals, Inc. | Methods and systems for scaled chromatography |
| WO2026006495A1 (en) | 2024-06-25 | 2026-01-02 | Alloy Therapeutics, Inc. | Anti-wt1/hla-a2 antibody and uses thereof |
| WO2026006492A2 (en) | 2024-06-25 | 2026-01-02 | Ypsilon Therapeutics, Inc. | Anti-prame/hla-a2 antibodies and uses thereof |
| WO2026015612A1 (en) | 2024-07-10 | 2026-01-15 | Regeneron Pharmaceuticals, Inc. | Methods of treating smarcb1-deficient cancers |
| WO2026025028A1 (en) | 2024-07-26 | 2026-01-29 | Regeneron Pharmaceuticals, Inc. | Methods of making ultra-high concentrated protein formulations using lyophilization |
Family Cites Families (140)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4361549A (en) | 1979-04-26 | 1982-11-30 | Ortho Pharmaceutical Corporation | Complement-fixing monoclonal antibody to human T cells, and methods of preparing same |
| FR2593830B1 (fr) | 1986-02-06 | 1988-04-08 | Snecma | Superalliage a matrice a base de nickel notamment elabore en metallurgie des poudres et disque de turbomachine constitue en cet alliage |
| US6893625B1 (en) | 1986-10-27 | 2005-05-17 | Royalty Pharma Finance Trust | Chimeric antibody with specificity to human B cell surface antigen |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| WO1989007142A1 (en) | 1988-02-05 | 1989-08-10 | Morrison Sherie L | Domain-modified constant region antibodies |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
| EP1005870B1 (en) | 1992-11-13 | 2009-01-21 | Biogen Idec Inc. | Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
| US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
| DK0826696T3 (da) | 1996-09-03 | 2002-09-23 | Gsf Forschungszentrum Umwelt | Anvendelse af bi- og trispecifikke antistoffer til inducering af en tumorimmunitet |
| PL199659B1 (pl) | 1998-02-25 | 2008-10-31 | Merck Patent Gmbh | Białko fuzyjne przeciwciała hu-KS IL2, cząsteczka DNA kodująca białko fuzyjne przeciwciała hu-KS IL2 i sposób wytwarzania białka fuzyjnego przeciwciała hu-KS IL2 |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| DK1071752T3 (da) | 1998-04-21 | 2003-10-20 | Micromet Ag | CD19xCD3-specifikke polypeptider og anvendelsen deraf |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| KR101023367B1 (ko) | 1998-08-11 | 2011-03-18 | 바이오겐 아이덱 인크. | Ｂ-세포 림프종을 치료하기 위한 항-ｃｄ２０ 항체를 포함하는 약제 |
| US6224866B1 (en) | 1998-10-07 | 2001-05-01 | Biocrystal Ltd. | Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors |
| US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| KR101077001B1 (ko) | 1999-01-15 | 2011-10-26 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| EP1176195B1 (en) | 1999-04-09 | 2013-05-22 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| HK1043312B (en) | 1999-05-07 | 2006-07-28 | Genentech, Inc. | Treatment of autoimmune diseases with antagonists which bind to b cell surface markers |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| ITMI991299A1 (it) | 1999-06-11 | 2000-12-11 | Consiglio Nazionale Ricerche | Uso di anticorpi contro antigeni di superficie per il trattamento della malattia trapianto contro ospite |
| US7396917B2 (en) | 2000-12-05 | 2008-07-08 | Alexion Pharmaceuticals, Inc. | Rationally designed antibodies |
| EP1395605B8 (en) | 2001-03-09 | 2014-12-17 | Iterative Therapeutics, Inc. | Polymeric immunoglobulin fusion proteins that target low-affinity fcgamma receptors |
| CA2461631A1 (en) | 2001-09-28 | 2003-04-03 | Elusys Therapeutics, Inc. | Methods and compositions for prevention, diagnosis, and treatment of cancer using bispecific molecules |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| CA2476166C (en) | 2002-02-14 | 2011-11-15 | Immunomedics, Inc. | Anti-cd20 antibodies and fusion proteins thereof and methods of use |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US8673589B2 (en) | 2002-05-29 | 2014-03-18 | Regeneron Pharmaceuticals, Inc. | Inducible eukaryotic expression system |
| EP1400534B1 (en) | 2002-09-10 | 2015-10-28 | Affimed GmbH | Human CD3-specific antibody with immunosuppressive properties |
| US7820166B2 (en) | 2002-10-11 | 2010-10-26 | Micromet Ag | Potent T cell modulating molecules |
| PL216630B1 (pl) | 2002-10-17 | 2014-04-30 | Genmab As | Izolowane ludzkie przeciwciało monoklonalne wiążące ludzki CD20, związane z tym przeciwciałem transfektoma, komórka gospodarza, transgeniczne zwierzę lub roślina, kompozycja, immunokoniugat, cząsteczka bispecyficzna, wektor ekspresyjny, kompozycja farmaceutyczna, zastosowanie medyczne, zestaw oraz przeciwciało antyidiotypowe i jego zastosowanie |
| US7608260B2 (en) | 2003-01-06 | 2009-10-27 | Medimmune, Llc | Stabilized immunoglobulins |
| US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| EP2368578A1 (en) | 2003-01-09 | 2011-09-28 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
| WO2005000901A2 (en) | 2003-05-09 | 2005-01-06 | Duke University | Cd20-specific antibodies and methods of employing same |
| AR044388A1 (es) | 2003-05-20 | 2005-09-07 | Applied Molecular Evolution | Moleculas de union a cd20 |
| CA2527878A1 (en) | 2003-05-30 | 2005-01-27 | Alexion Pharmaceuticals, Inc. | Antibodies and fusion proteins that include engineered constant regions |
| WO2004106383A1 (en) | 2003-05-31 | 2004-12-09 | Micromet Ag | Pharmaceutical composition comprising a bispecific antibody for epcam |
| CA2523716C (en) | 2003-05-31 | 2014-11-25 | Micromet Ag | Human anti-human cd3 binding molecules |
| US20050163782A1 (en) | 2003-06-27 | 2005-07-28 | Biogen Idec Ma Inc. | Modified binding molecules comprising connecting peptides |
| KR20060132554A (ko) | 2003-08-29 | 2006-12-21 | 제넨테크, 인크. | 안과 질병의 항-ｃｄ２０ 치료 |
| US8399618B2 (en) | 2004-10-21 | 2013-03-19 | Xencor, Inc. | Immunoglobulin insertions, deletions, and substitutions |
| JP4948174B2 (ja) | 2003-10-16 | 2012-06-06 | マイクロメット アクツィエン ゲゼルシャフト | 多重特異的脱免疫ｃｄ３−結合物質 |
| US20050191297A1 (en) | 2003-12-19 | 2005-09-01 | Genentech, Inc. | Detection of CD20 in transplant rejection |
| US7276585B2 (en) | 2004-03-24 | 2007-10-02 | Xencor, Inc. | Immunoglobulin variants outside the Fc region |
| CN1942483B (zh) | 2004-04-13 | 2012-09-26 | 弗·哈夫曼-拉罗切有限公司 | 抗p型选凝素抗体 |
| US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
| ZA200608982B (en) | 2004-05-05 | 2008-06-25 | Genentech Inc | Preventing autoimmune disease by using an anti-CD20 antibody |
| CA2569509C (en) * | 2004-06-03 | 2014-08-12 | Novimmune S.A. | Anti-cd3 antibodies and methods of use thereof |
| PA8635501A1 (es) | 2004-06-04 | 2006-06-02 | Genentech Inc | Uso de un anticuerpo para el tratamiento del lupus |
| ZA200702335B (en) | 2004-10-05 | 2009-05-27 | Genentech Inc | Method for treating vasculitis |
| AR051836A1 (es) | 2004-11-30 | 2007-02-14 | Centocor Inc | Antagonistas de receptor 3 simil toll metodos y usos |
| US20120189643A1 (en) | 2004-11-30 | 2012-07-26 | Carton Jill M | Toll Like Receptor 3 Antagonists, Methods and Uses |
| WO2006074399A2 (en) | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
| US7700099B2 (en) | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
| TW200714289A (en) | 2005-02-28 | 2007-04-16 | Genentech Inc | Treatment of bone disorders |
| AR053579A1 (es) | 2005-04-15 | 2007-05-09 | Genentech Inc | Tratamiento de la enfermedad inflamatoria intestinal (eii) |
| ZA200708857B (en) | 2005-04-22 | 2009-01-28 | Genentech Inc | Method for treating dementia or alzheimer's disease with a CD30 antibody |
| US20070014720A1 (en) | 2005-06-02 | 2007-01-18 | Gadi Gazit-Bornstein | Antibodies directed to CD20 and uses thereof |
| EP2500357A3 (en) | 2005-08-19 | 2012-10-24 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| EP2500352A1 (en) | 2005-08-19 | 2012-09-19 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| EP1940881B1 (en) | 2005-10-11 | 2016-11-30 | Amgen Research (Munich) GmbH | Compositions comprising cross-species-specific antibodies and uses thereof |
| JP2009511067A (ja) | 2005-10-14 | 2009-03-19 | メディミューン，エルエルシー | 抗体ライブラリーの細胞提示 |
| ES2586825T3 (es) | 2006-01-12 | 2016-10-19 | Alexion Pharmaceuticals, Inc. | Anticuerpos para OX-2/CD200 y usos de los mismos |
| EP1820513A1 (en) | 2006-02-15 | 2007-08-22 | Trion Pharma Gmbh | Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies |
| SI2359834T1 (sl) | 2006-03-15 | 2017-02-28 | Alexion Pharmaceuticals, Inc. | Zdravljenje pacientov,ki imajo paroksizmalno nočno hemoglobinurijo, z zaviralcem komplementa |
| AU2007227963A1 (en) | 2006-03-23 | 2007-09-27 | Kyowa Hakko Kirin Co., Ltd. | Agonist antibody to human thrombopoietin receptor |
| RS52176B (sr) | 2006-06-02 | 2012-08-31 | Regeneron Pharmaceuticals Inc. | Antitela visokog afiniteta prema humanom il-6 receptoru |
| NO347649B1 (no) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| EP2139924B1 (en) | 2007-03-29 | 2016-07-06 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| AU2008234019B2 (en) | 2007-04-03 | 2014-05-29 | Amgen Research (Munich) Gmbh | Cross-species-specific bispecific binders |
| WO2008119567A2 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific cd3-epsilon binding domain |
| KR20100021601A (ko) | 2007-05-14 | 2010-02-25 | 바이오겐 아이덱 엠에이 인코포레이티드 | 단일-쇄 Ｆｃ(ＳｃＦｃ) 부분, 이를 포함하는 결합 폴리펩타이드, 및 이에 관련된 방법 |
| CA2687377C (en) | 2007-05-30 | 2013-05-14 | Genexine Co., Ltd. | Immunoglobulin fusion proteins |
| EP2170951A2 (en) | 2007-05-31 | 2010-04-07 | Genmab A/S | Recombinant non glycosylated monovalent half-antibodies obtained by molecular engineering |
| EP2666787B1 (en) | 2007-05-31 | 2022-02-09 | Genmab A/S | STABLE IgG4 ANTIBODIES |
| WO2009006520A1 (en) | 2007-07-03 | 2009-01-08 | Medimmune, Llc | Hinge domain engineering |
| US7879984B2 (en) | 2007-07-31 | 2011-02-01 | Regeneron Pharmaceuticals, Inc. | Human antibodies to human CD20 and method of using thereof |
| KR101709488B1 (ko) | 2007-08-10 | 2017-02-24 | 리제너론 파아마슈티컬스, 인크. | 인간 신경성장인자에 대한 고친화성 인간 항체 |
| MX2010002406A (es) | 2007-09-05 | 2010-04-27 | Hoffmann La Roche | Terapia de combinacion con anticuerpos anti-cd20 de tipo i y de tipo ii. |
| WO2009041621A1 (ja) | 2007-09-26 | 2009-04-02 | Chugai Seiyaku Kabushiki Kaisha | 抗il-6レセプター抗体 |
| DK3059246T3 (en) | 2007-09-26 | 2018-10-01 | Chugai Pharmaceutical Co Ltd | Modified constant region of an antibody |
| EP2254911B1 (en) | 2008-02-20 | 2015-11-25 | Novo Nordisk A/S | Humanized anti-c5ar antibodies |
| WO2009106096A1 (en) | 2008-02-27 | 2009-09-03 | Fresenius Biotech Gmbh | Treatment of resistant tumors with trifunctional antibodies |
| CA2742861A1 (en) | 2008-11-06 | 2010-05-14 | Alexion Pharmaceuticals, Inc. | Engineered antibodies with reduced immunogenicity and methods of making |
| CN102209729B (zh) | 2008-11-07 | 2016-05-25 | 安进研发（慕尼黑）股份有限公司 | 小儿急性淋巴细胞白血病的治疗方法 |
| AR074438A1 (es) | 2008-12-02 | 2011-01-19 | Pf Medicament | Proceso para la modulacion de la actividad antagonista de un anticuerpo monoclonal |
| WO2010063785A2 (en) | 2008-12-03 | 2010-06-10 | Genmab A/S | Antibody variants having modifications in the constant region |
| WO2010085682A2 (en) | 2009-01-23 | 2010-07-29 | Biogen Idec Ma Inc. | Stabilized fc polypeptides with reduced effector function and methods of use |
| EP2409991B1 (en) | 2009-03-19 | 2017-05-03 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
| JP5787446B2 (ja) | 2009-03-19 | 2015-09-30 | 中外製薬株式会社 | 抗体定常領域改変体 |
| KR101747103B1 (ko) * | 2009-06-26 | 2017-06-14 | 리제너론 파마슈티칼스 인코포레이티드 | 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체 |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| US10150808B2 (en) | 2009-09-24 | 2018-12-11 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant regions |
| PL2506871T3 (pl) | 2009-11-30 | 2017-03-31 | Janssen Biotech, Inc | Przeciwciała ze zmutowanymi regionami Fc i utraconymi funkcjami efektorowymi |
| US20130129723A1 (en) | 2009-12-29 | 2013-05-23 | Emergent Product Development Seattle, Llc | Heterodimer Binding Proteins and Uses Thereof |
| SG181952A1 (en) | 2009-12-29 | 2012-07-30 | Emergent Product Dev Seattle | Heterodimer binding proteins and uses thereof |
| US10143186B2 (en) | 2010-02-08 | 2018-12-04 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
| CN102167741B (zh) * | 2010-02-25 | 2014-05-14 | 上海百迈博制药有限公司 | 一种全人源抗TNF-α单克隆抗体、其制备方法及用途 |
| EP2543730B1 (en) | 2010-03-04 | 2018-10-31 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
| MX341925B (es) | 2010-03-29 | 2016-09-07 | Zymeworks Inc | Anticuerpos con funcion efectora suprimida o mejorada. |
| EP2563812A4 (en) | 2010-04-30 | 2016-01-13 | Alexion Pharma Inc | ANTIBODIES WITH REDUCED IMMUNOGENITY IN HUMANS |
| GB201014033D0 (en) | 2010-08-20 | 2010-10-06 | Ucb Pharma Sa | Biological products |
| CN103249742B (zh) | 2010-09-16 | 2017-04-12 | 巴利奥医药股份公司 | 抗人肿瘤坏死因子1型受体抗体 |
| PT3434767T (pt) * | 2010-11-30 | 2026-01-23 | Chugai Pharmaceutical Co Ltd | Agente terapêutico indutor de citotoxicidade |
| EP2654780B1 (en) | 2010-12-23 | 2017-02-01 | Janssen Biotech, Inc. | Active protease-resistant antibody fc mutants |
| SG10201913690SA (en) | 2011-02-08 | 2020-03-30 | Medimmune Llc | Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use |
| BR112013024574B1 (pt) | 2011-03-29 | 2022-08-09 | Roche Glycart Ag | Anticorpo e uso do anticorpo |
| AU2012245116A1 (en) * | 2011-04-20 | 2013-11-07 | Genmab A/S | Bispecific antibodies against HER2 and CD3 |
| US9738707B2 (en) | 2011-07-15 | 2017-08-22 | Biogen Ma Inc. | Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto |
| CN107586340B (zh) | 2011-08-23 | 2022-01-21 | 罗切格利卡特公司 | 对t细胞活化性抗原和肿瘤抗原特异性的双特异性抗体及使用方法 |
| HK1203528A1 (zh) | 2012-01-27 | 2015-10-30 | Gliknik Inc. | 包含igg2鉸鏈結構域的融合蛋白 |
| JO3820B1 (ar) | 2012-05-03 | 2021-01-31 | Regeneron Pharma | أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها |
| CN104582476B (zh) | 2012-06-05 | 2017-03-08 | 瑞泽恩制药公司 | 使用共同轻链制备完全人双特异性抗体的方法 |
| US20140154253A1 (en) * | 2012-07-13 | 2014-06-05 | Zymeworks Inc. | Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs |
| US20150203591A1 (en) * | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
| JOP20200236A1 (ar) * | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| HRP20181717T1 (hr) | 2012-09-27 | 2018-12-28 | Merus N.V. | Bispecifična igg protutijela kao aktivatori t stanice |
| EP2905290B1 (en) | 2012-10-05 | 2019-12-04 | Kyowa Kirin Co., Ltd. | Heterodimeric protein composition |
| BR112015007120A2 (pt) | 2012-10-08 | 2017-12-12 | Roche Glycart Ag | anticorpo biespecífico, composição farmacêutica, uso, célula hospedeira e método de produção de um anticorpo |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| HUE048722T2 (hu) * | 2013-07-05 | 2020-08-28 | Genmab As | Humanizált vagy kiméra CD3 ellenanyagok |
| US20160355588A1 (en) * | 2013-07-12 | 2016-12-08 | Zymeworks Inc. | Bispecific CD3 and CD19 Antigen Binding Constructs |
| KR102225489B1 (ko) * | 2013-12-17 | 2021-03-10 | 제넨테크, 인크. | 항-cd3 항체 및 이의 사용 방법 |
| CA2925677A1 (en) | 2013-12-20 | 2015-06-25 | F. Hoffmann-La Roche Ag | Bispecific her2 antibodies and methods of use |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| TWI701042B (zh) * | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| AU2015350075B2 (en) | 2014-11-17 | 2021-06-03 | Regeneron Pharmaceuticals, Inc. | Methods for tumor treatment using CD3xCD20 bispecific antibody |
| US10556952B2 (en) | 2015-03-30 | 2020-02-11 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to Fc gamma receptors |
| GB201506407D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| TWI784917B (zh) | 2015-09-23 | 2022-11-21 | 美商再生元醫藥公司 | 最優化抗ｃｄ３雙特異性抗體及其用途 |
| MA44146B1 (fr) * | 2015-12-22 | 2023-10-31 | Regeneron Pharma | Combinaison d'anticorps anti-pd-1 et d'anticorps bispécifiques anti-cd20/anti-cd3 pour traiter le cancer |
| EA201891495A1 (ru) | 2015-12-22 | 2018-11-30 | Ридженерон Фармасьютикалз, Инк. | Биспецифические анти-cd20/анти-cd3 антитела для лечения острого лимфобластного лейкоза |
| US11466094B2 (en) | 2016-11-15 | 2022-10-11 | Genentech, Inc. | Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies |
| IL280875B2 (en) * | 2018-08-31 | 2024-12-01 | Regeneron Pharma | Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies |
-
2015
- 2015-03-17 TW TW104108403A patent/TWI701042B/zh active
- 2015-03-17 TW TW109123150A patent/TWI754319B/zh active
- 2015-03-18 CN CN201580025902.3A patent/CN106459214B/zh active Active
- 2015-03-18 DK DK19188693.6T patent/DK3594238T3/da active
- 2015-03-18 EP EP15714116.9A patent/EP3119808B1/en active Active
- 2015-03-18 ME MEP-2019-303A patent/ME03544B/me unknown
- 2015-03-18 HR HRP20192170TT patent/HRP20192170T1/hr unknown
- 2015-03-18 AU AU2015231295A patent/AU2015231295C1/en active Active
- 2015-03-18 JP JP2016557946A patent/JP6559697B2/ja active Active
- 2015-03-18 EP EP19188693.6A patent/EP3594238B1/en active Active
- 2015-03-18 LT LTEP19188693.6T patent/LT3594238T/lt unknown
- 2015-03-18 KR KR1020167029122A patent/KR102435081B1/ko active Active
- 2015-03-18 EA EA201691858A patent/EA035164B1/ru unknown
- 2015-03-18 SM SM20190662T patent/SMT201900662T1/it unknown
- 2015-03-18 CA CA2943084A patent/CA2943084C/en active Active
- 2015-03-18 SI SI201531600T patent/SI3594238T1/sl unknown
- 2015-03-18 SM SM20210297T patent/SMT202100297T1/it unknown
- 2015-03-18 PT PT191886936T patent/PT3594238T/pt unknown
- 2015-03-18 MX MX2016012094A patent/MX373927B/es active IP Right Grant
- 2015-03-18 EP EP21151864.2A patent/EP3848395A1/en active Pending
- 2015-03-18 RS RS20191516A patent/RS59642B1/sr unknown
- 2015-03-18 SI SI201530916T patent/SI3119808T1/sl unknown
- 2015-03-18 HU HUE19188693A patent/HUE054397T2/hu unknown
- 2015-03-18 PL PL19188693T patent/PL3594238T3/pl unknown
- 2015-03-18 CN CN202110412625.9A patent/CN113045669B/zh active Active
- 2015-03-18 US US14/661,334 patent/US10550193B2/en active Active
- 2015-03-18 LT LTEP15714116.9T patent/LT3119808T/lt unknown
- 2015-03-18 PT PT157141169T patent/PT3119808T/pt unknown
- 2015-03-18 PL PL15714116T patent/PL3119808T3/pl unknown
- 2015-03-18 HU HUE15714116A patent/HUE046505T2/hu unknown
- 2015-03-18 WO PCT/US2015/021322 patent/WO2015143079A1/en not_active Ceased
- 2015-03-18 RS RS20210618A patent/RS61856B1/sr unknown
- 2015-03-18 MA MA055629A patent/MA55629A/fr unknown
- 2015-03-18 ES ES15714116T patent/ES2752156T3/es active Active
- 2015-03-18 ES ES19188693T patent/ES2868330T3/es active Active
- 2015-03-18 DK DK15714116T patent/DK3119808T3/da active
-
2016
- 2016-09-15 MX MX2020004410A patent/MX2020004410A/es unknown
- 2016-09-15 IL IL247845A patent/IL247845B/en active IP Right Grant
- 2016-09-23 ZA ZA2016/06597A patent/ZA201606597B/en unknown
-
2019
- 2019-07-16 JP JP2019130949A patent/JP6831426B2/ja active Active
- 2019-11-21 CY CY20191101220T patent/CY1122315T1/el unknown
- 2019-12-17 US US16/716,980 patent/US11434300B2/en active Active
-
2020
- 2020-02-10 IL IL272572A patent/IL272572B/en active IP Right Grant
-
2021
- 2021-05-06 CY CY20211100383T patent/CY1124090T1/el unknown
-
2022
- 2022-07-27 US US17/875,295 patent/US20230220101A1/en active Pending
-
2024
- 2024-12-06 NL NL301302C patent/NL301302I2/nl unknown
- 2024-12-12 NO NO2024056C patent/NO2024056I1/no unknown
- 2024-12-12 FI FIC20240044C patent/FIC20240044I1/fi unknown
- 2024-12-19 LT LTPA2024540C patent/LTPA2024540I1/lt unknown
-
2025
- 2025-01-02 HU HUS2500001C patent/HUS2500001I1/hu unknown
- 2025-01-07 FR FR25C1001C patent/FR25C1001I2/fr active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017509643A5 (enExample) | ||
| US20230192847A1 (en) | Tigit antibodies, encoding nucleic acids and methods of using said antibodies in vivo | |
| US12209128B2 (en) | Anti-PD-L1 antibodies | |
| US20230287117A1 (en) | Heavy Chain Constant Regions with Reduced Binding to Fc Gamma Receptors | |
| US20220226469A1 (en) | Therapeutic sirp-alpha antibodies | |
| US11965026B2 (en) | Anti-PD-L1 and IL-2 cytokines | |
| HRP20192170T1 (hr) | Pripravci antitijela za liječenje tumora | |
| Patel et al. | IgG isotype, glycosylation, and EGFR expression determine the induction of antibody-dependent cellular cytotoxicity in vitro by cetuximab | |
| KR20200021474A (ko) | 삼중 조합 항체 치료제 | |
| AU2016332725A1 (en) | PD-1 binding proteins and methods of use thereof | |
| JP2013528357A5 (enExample) | ||
| RU2012145183A (ru) | Антитела с повышенной или пониженной эффекторной функцией | |
| JP2023511482A (ja) | Ｃｄ２７６抗原の抗体ターゲティング、および他のモジュレーター、ならびにその使用 | |
| US20230279108A1 (en) | Therapeutic sirp-alpha antibodies | |
| JP2023025215A (ja) | Ｐｄ－ｌ１抗体およびｔａ－ｍｕｃ１抗体 | |
| TW202321304A (zh) | 抗ｃｃｒ８抗體 | |
| AU2021325430A1 (en) | Antibodies against ILT2 and use thereof | |
| US20230400467A1 (en) | Pvrl2 and/or pvrig as biomarkers for treatment | |
| KR20230098317A (ko) | 표적 세포가 제한되는, 공동자극, 이중특이적 및 2가 항-cd28 항체 |